Main content area

Targeting the relaxin/insulin-like family peptide receptor 1 and 2 with small molecule compounds

Ng, Hooi Hooi, Esteban-Lopez, Maria, Agoulnik, Alexander I.
Molecular and cellular endocrinology 2019 v.487 pp. 40-44
G-protein coupled receptors, agonists, cardiovascular diseases, drugs, half life, intravenous injection, ligands, liver cirrhosis, muscles, peptide receptors, relaxin, therapeutics
The peptide hormone relaxin has beneficial roles in several organs through its action on its cognate G protein-coupled receptor, RXFP1. Relaxin administration is limited to intravenous, subcutaneous, intramuscular, or spinal injection. Another drawback of peptide-based therapy is the short half-life, which requires continuous delivery of the drug to achieve efficient concentration in target organs. The discovery of a non-peptide small molecule agonist of RXFP1, ML290, provides an alternative to the natural ligand. This review summarizes the development of ML290 and its potential future therapeutic applications in various diseases, including liver fibrosis and cardiovascular diseases. We also discuss the development of small molecule agonists targeting the insulin-like 3 receptor, RXFP2, and propose the potential use of these small molecules in the context of bone and muscle remodeling.